ACADIA Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
ACADIA to Host Conference Call and Webcast on Tuesday, August 5,
2008, at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--July 29, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2008 on Tuesday, August 5, 2008, before the U.S. financial markets open. ACADIA's management will host a conference call and webcast on Tuesday, August 5, 2008, at 8:30 a.m. Eastern Time to discuss ACADIA's financial results and development programs.
The conference call may be accessed by dialing 866-825-1709 for participants in the U.S. or Canada and 617-213-8060 for international callers (reference passcode 62862758). A telephone replay of the conference call may be accessed through August 19, 2008 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 47546867). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until August 19, 2008.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five clinical programs as well as a portfolio of preclinical and discovery assets directed at diseases with large unmet medical needs, including Parkinson's disease psychosis, schizophrenia, sleep maintenance insomnia, chronic pain, and glaucoma. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Director, Investor Relations Thomas H. Aasen, Vice President and Chief Financial Officer 858-558-2871 SOURCE: ACADIA Pharmaceuticals Inc.